📰 Pharma Corp News
Page 4 - Pharma Corp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharma Corp. Real-time updates on events, politics, business and more.
May 30, 2023
/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel...
May 30, 2023
SEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. , a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related... | June 7, 2023
May 15, 2023
A number of firms have modified their ratings and price targets on shares of CTI BioPharma (NASDAQ: CTIC) recently: 5/15/2023 – CTI BioPharma was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. 5/11/2023 – CTI BioPharma was downgraded by analysts at JMP Securities from an “outperform” rating to a […]
May 14, 2023
NEW YORK, May 13, 2023 (GLOBE NEWSWIRE) -- CTI BioPharma Corp (NASDAQ: CTIC) Lifshitz Law PLLC announces an investigation into possible breach...
May 10, 2023
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTIs Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma , a commercial... | May 10, 2023
May 10, 2023
/PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted...
May 10, 2023
TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT is made and entered into as of May 10, 2023 by and among Swedish Orphan Biovitrum AB , a Swedish... | May 10, 2023
May 10, 2023
Swedish Orphan Biovitrum AB agreed to buy US biotech CTI BioPharma Corp., which develops therapies for blood-related cancers, in a deal valued at $1.7…
April 11, 2023
During the forecast period 2023 to 2033, the Secondary Myelofibrosis Therapeutics Market is expected to grow at a value of 6.3% CAGR, according to Future Market Insights. By the year 2033, the global market for Secondary myelofibrosis therapeutics is expected to rise up to a market valuation of US$ 2.74 Billion. Gro...
March 15, 2023
/PRNewswire/ -- Global Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market 2023-2027 The analyst has been monitoring the diffuse large B-Cell Lymphoma...